EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
- Written by PR Newswire
![]() |
PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and corporate growth.
This year, EpiVax expanded the breadth of its immunogenicity risk assessment...
Read more: EpiVax Drives Immunogenicity Innovation in 2024: Year in Review















